Everything below concerns Investigational drug. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-25. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Many of the characteristics of micelles differ from those of bulk solvents. For example, the micelles are, by nature, spatially heterogeneous with a hydrocarbon, nearly anhydrous core and a highly solvated, polar head group. They have a high surface-to-volume ratio due to their small size and generally spherical shape. Their surrounding environment (pH, ionic strength, buffer ion, presence of a co-solvent, and temperature) has an influence on their size, shape, critical micelle concentration, aggregation number and other properties. Another important property of micelles is the Krafft point, the temperature at which the solubility of the surfactant is equal to its CMC. For HPLC applications involving micelles, it is best to choose a surfactant with a low Krafft point and CMC. A high CMC would require a high concentration of surfactant which would increase the viscosity of the mobile phase, an undesirable condition. Additionally, a Krafft point should be well below room temperature to avoid having to apply heat to the mobile phase. To avoid potential interference with absorption detectors, a surfactant should also have a small molar absorptivity at the chosen wavelength of analysis. Light scattering should not be a concern due to the small size, a few nanometers, of the micelle. The effect of organic additives on micellar properties is another important consideration. A small amount of organic solvent is often added to the mobile phase to help improve efficiency and to improve separations of compounds. Care needs to be taken when determining how much organic to add.
As for SDF-1α, the release of lysine decreases its ability to function, so this enzyme acts as a regulator of activity; SDF-1α is normally important in hematopoietic stem cell trafficking. For plasminogen receptors, cleaving lysine prevents plasminogen's activation into plasmin. Lysine carboxypeptidase regulates enkephalin by reducing its affinity for kappa opioid receptors and consequently making it delta receptor specific. It is also suspected that epidermal growth factor (and possibly other growth factors), acts as a substrate since it is metabolized by the cleavage of C-terminal arginine. Other lesser studied substrates include fibrinopeptides which are involved in blood clotting. This enzyme is extremely important for proper functioning of the body. There are no records of a person who is completely missing lysine carboxypeptidase and lower than normal levels of the enzyme have been linked to disorders such as angioneurotic edema.
=== Circular chromatography === A circular filter paper is taken and the sample is deposited at the center of the paper. After drying the spot, the filter paper is tied horizontally on a Petri dish containing solvent, so that the wick of the paper is dipped in the solvent. The solvent rises through the wick and the components are separated into concentric rings.
Sources: en.wikipedia.org
NanoSIMS was used to study and prove for the first time the nitrogen fixing abilities of bacteria and archaea from the deep ocean by supplying 15N nitrogen contain compounds to sediment samples. NanoSIMS can also be used to estimate growth rate of organisms, as the amount of carbon or other substrate accumulated inside the cell allows for estimation of how much biomass is being generated.
Ulotaront (INNTooltip International Nonproprietary Name; developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals (which was subsequently merged into Sumitomo Pharma) using PsychoGenics' behavior and AI-based phenotypic drug discovery platform, SmartCube. Ulotaront is in phase III clinical trial for schizophrenia, phase II/III for generalized anxiety disorder and major depressive disorder, and discontinued for narcolepsy and psychotic disorders. Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Ulotaront was awarded a Breakthrough Therapy designation due to its increased efficacy and greatly reduced side effects compared to current treatments.
Oxytocin stimulates powerful uterine contractions, which trigger labour and delivery of an infant, and milk ejection in nursing women. Its release is mediated reflexively by the hypothalamus and represents a positive feedback mechanism. Antidiuretic hormone stimulates the kidney tubules to reabsorb and conserve water, resulting in small volumes of highly concentrated urine and decreased plasma osmolality. Antidiuretic hormone is released in response to high solute concentrations in the blood and inhibited by low solute concentrations in the blood. Hyposecretion results in diabetes insipidus.
Sources: en.wikipedia.org
== Pre-atomic chemistry == Working in the late 17th century, Robert Boyle developed the concept of a chemical element as substance different from a compound. Near the end of the 18th century, a number of important developments in chemistry emerged without referring to the notion of an atomic theory. The first was Antoine Lavoisier who showed that compounds consist of elements in constant proportion, redefining an element as a substance which scientists could not decompose into simpler substances by experimentation. This brought an end to the ancient idea of the elements of matter being fire, earth, air, and water, which had no experimental support. Lavoisier showed that water can be decomposed into hydrogen and oxygen, which in turn he could not decompose into anything simpler, thereby proving these are elements. Lavoisier also defined the law of conservation of mass, which states that in a chemical reaction, matter does not appear nor disappear into thin air; the total mass remains the same even if the substances involved were transformed. In 1797 the French chemist Joseph Proust established the law of definite proportions, which states that if a compound is broken down into its constituent chemical elements, then the masses of those constituents will always have the same proportions by weight, regardless of the quantity or source of the original compound. This definition distinguished compounds from mixtures.
=== Lebanon === Hitchens described Lebanon as "the most plural society in the region" and criticized the Syrian regime for continuing to manipulate the country by proxies and by surrogates notably Hezbollah and the SSNP. In an article written on Slate, Hitchens stated:
Scarification involves scratching, etching, burning/branding, or superficially cutting designs, pictures, or words into the skin as a permanent body modification or body art. The body modification can take roughly 6–12 months to heal. In the process of body scarification, scars are purposely formed by cutting or branding the skin by various methods (sometimes using further sequential aggravating wound-healing methods at timed intervals, like irritation). Scarification is sometimes called cicatrization.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.